GEN Exclusives

More »

GEN News Highlights

More »
Jul 13, 2012

Janssen Taps Genmab for Bispecific Antibody Platform

  • Janssen Biotech is making a $3.5 million up-front payment to Genmab to access the latter’s DuoBody platform for the development of bispecific antibodies against multiple target combinations. The deal follows just six weeks after Genmab inked a DuoBody partnership with Novartis.

    Under terms of the latest collaboration with Janssen, the latter will fully fund all Genmab’s research on up to 10 DuoBody programs. The firm could earn up to another $175 million in potential milestone and license payments for each product, plus future sales royalties.

    “Since the introduction of our DuoBody platform in 2010, we have believed in its potential to become the preferred technology for next-generation bispecific antibody therapeutics,” comments CEO Jan van de Winkel, Ph.D. “Today’s announcement is another indicator that the pharmaceutical industry recognizes our leadership in the therapeutic antibody field.”

Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

The Triple Package and Success

One theory for explaining “success," put forward by Amy Chua Jed Rubenfeld, posits cultural traits such as a superiority complex, personal insecurity and impulse control. Union College professors Joshua Hart and Christopher Chabris counter that intelligence, conscientiousness, and economic advantage are the most likely elements of success, regardless of ethnicity. Do you think that Hart-Chabris make a better argument for achieving success than the Chua-Rubenfeld theory?

More »